Souhaitez-vous accéder aux communiqués récents ?

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE...

Agomab today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants.

Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used...

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been...

"Not intended for US or UK audiences."Ingelheim, GermanyApproval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the absolute change...

Transpire Bio today announced that the U.S. FDA has granted orphan drug designation (ODD) for two of its products in development.

Ingelheim, Germany/Ridgefield, Connecticut, U.S. Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.1Approval is based on results from two...

A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without...

No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data Phase 2a study fully enrolled; Topline data on track for Q3 2025 Currently available...

Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's...